IMATINIB TEVA PHARMA

Main information

  • Trade name:
  • IMATINIB TEVA PHARMA Film-coated tablet 100MG
  • Dosage:
  • 100MG
  • Pharmaceutical form:
  • Film-coated tablet
  • Administration route:
  • Oral use
  • Units in package:
  • 120 II Blister
  • Prescription type:
  • with prescription
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • IMATINIB TEVA PHARMA Film-coated tablet 100MG
    Czech Republic
  • Language:
  • English

Therapeutic information

  • Therapeutic area:
  • IMATINIB
  • Product summary:
  • IMATINIB TEVA PHARMA

Other information

Status

  • Source:
  • SUKL - Státní ústav pro kontrolu léčiv
  • Authorization status:
  • R - active MA/authorised medicinal product
  • Authorization number:
  • 44/ 068/14-C
  • Last update:
  • 17-01-2018

2-10-2018

Lamivudine Teva Pharma B.V. (Teva B.V.)

Lamivudine Teva Pharma B.V. (Teva B.V.)

Lamivudine Teva Pharma B.V. (Active substance: Lamivudine) - Centralised - Yearly update - Commission Decision (2018)6476 of Tue, 02 Oct 2018

Europe -DG Health and Food Safety

27-6-2018

Glivec (Novartis Europharm Limited)

Glivec (Novartis Europharm Limited)

Glivec (Active substance: Imatinib) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4087 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/406/T/110

Europe -DG Health and Food Safety

15-5-2018

Imatinib Teva B.V. (Teva B.V.)

Imatinib Teva B.V. (Teva B.V.)

Imatinib Teva B.V. (Active substance: imatinib) - Centralised - Withdrawal - Commission Decision (2018)3008 of Tue, 15 May 2018

Europe -DG Health and Food Safety